Mimotope peptide modified pompon mum-like magnetic microparticles for precise recognition, capture and biotransformation analysis of rituximab in biological fluids

Yang, Jiawen; Zhou, Aixuan; Li, Minyi; He, Qiaoxian; Zhou, Jingwei; Crommen, Jacques; Wang, Wentao; Jiang, Zhengjin; Wang, Qiqin

doi:10.1016/j.apsb.2023.10.018

Cited by 6 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 According to previous studies, an appropriate salt concentration (20 mM PB) and pH (8.0) can increase the surface tension of the solution and reduce electrostatic interactions with interfering proteins. 31 Therefore, the salt concentration (from 10 to 30 mM PB) and pH (from 6.0 to 8.0) of the washing buffer were systematically studied to ensure selective retention of antibodies. As shown in Figure 3B, HSA could not be completely removed at low concentrations of salt and pH, while too high concentrations of salt and pH resulted in the leakage of rituximab.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

“…The washing step is essential to remove impurities from complex samples . According to previous studies, an appropriate salt concentration (20 mM PB) and pH (8.0) can increase the surface tension of the solution and reduce electrostatic interactions with interfering proteins . Therefore, the salt concentration (from 10 to 30 mM PB) and pH (from 6.0 to 8.0) of the washing buffer were systematically studied to ensure selective retention of antibodies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Supramolecular Mimotope Peptide Nanofibers Promote Antibody–Ligand Polyvalent and Instantaneous Recognition for Biopharmaceutical Analysis

He,

Chen,

Zhao

et al. 2024

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

Peptide-based supramolecules exhibit great potential in various fields due to their improved target recognition ability and versatile functions. However, they still suffer from numerous challenges for the biopharmaceutical analysis, including poor selfassembly ability, undesirable ligand−antibody binding rates, and formidable target binding barriers caused by ligand crowding. To tackle these issues, a "polyvalent recognition" strategy employing the CD20 mimotope peptide derivative NBD-FFVLR-GS-WPRWLEN (acting on the CDR domains of rituximab) was proposed to develop supramolecular nanofibers for target antibody recognition. These nanofibers exhibited rapid self-assembly within only 1 min and robust stability. Their binding affinity (179 nM) for rituximab surpassed that of the monomeric peptide (7 μM) by over 38-fold, highlighting that high ligand density and potential polyvalent recognition can efficiently overcome the target binding barriers of traditional supramolecules. Moreover, these nanofibers exhibited an amazing "instantaneous capture" rate (within 15 s), a high recovery (93 ± 3%), and good specificity for the target antibody. High-efficiency enrichment of rituximab was achieved from cell culture medium with good recovery and reproducibility. Intriguingly, these peptide nanofibers combined with bottom-up proteomics were successful in tracking the deamidation of asparagine 55 (from 10 to 16%) on the rituximab heavy chain after 21 day incubation in human serum. In summary, this study may open up an avenue for the development of versatile mimotope peptide supramolecules for biorecognition and bioanalysis of biopharmaceuticals.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Supramolecular Mimotope Peptide Nanofibers Promote Antibody–Ligand Polyvalent and Instantaneous Recognition for Biopharmaceutical Analysis

He,

Chen,

Zhao

et al. 2024

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Approximately 15 years ago, peptide sequences specifically recognizing certain mAbs, such as trastuzumab, cetuximab, and rituximab, were successively screened by Ph.D.; similarity was demonstrated between the peptides and the epitopes recognized by the mAbs (Table 3). [63,64,66,73] Mimotopes can also be prepared using fragment structure or sequence information from the region in which the antigen binds to the mAb; the mimotopes yield detailed binding information [74] . Methods have been developed to predict conformational epitopes in antigens based on the antigen sequence (CBtope) or antigen structure (DiscoTope, BEpro, etc.)…”

Section: Bioreceptors Used To Recognize Mabsmentioning

confidence: 99%

Biosensing materials for monoclonal antibody detection: An overview

Zhang,

Fan,

Chai

et al. 2024

Responsive Materials

View full text Add to dashboard Cite

Considering the continuous advances in the synthesis and clinical applications of monoclonal antibodies (mAbs), precision therapies that employ mAbs are essential. In recent years, extensive efforts have been invested in developing novel strategies or technologies for detection of mAbs. Given the availability of advanced biosensing materials, various assemblies of multifunctional materials can be prepared by intelligent design when evaluating targets for mAbs. This article provides an overview of the recent advances and functional applications of biosensing materials for mAb detection. Subsequently, we present the approaches by which mAb receptors are combined with materials to construct stimulus‐responsive analytical platforms that evaluate the contents and activities of mAbs in biological systems, enabling real‐time monitoring and diagnosis that could facilitate administration of mAbs during treatment. Furthermore, the review examines various applications of biosensing for mAb detection and implications in real‐world contexts; it also discusses ongoing challenges and future prospects.

show abstract

Multiepitope recognition technology promotes the in-depth analysis of antibody‒drug conjugates

Lei,

Shen,

Chen

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Mimotope peptide modified pompon mum-like magnetic microparticles for precise recognition, capture and biotransformation analysis of rituximab in biological fluids

Cited by 6 publications

References 48 publications

Supramolecular Mimotope Peptide Nanofibers Promote Antibody–Ligand Polyvalent and Instantaneous Recognition for Biopharmaceutical Analysis

Supramolecular Mimotope Peptide Nanofibers Promote Antibody–Ligand Polyvalent and Instantaneous Recognition for Biopharmaceutical Analysis

Biosensing materials for monoclonal antibody detection: An overview

Multiepitope recognition technology promotes the in-depth analysis of antibody‒drug conjugates

Contact Info

Product

Resources

About